We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+4.46%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$6.63B
AUM Growth
+$3.92M
Cap. Flow
+$439M
Cap. Flow %
6.62%
Top 10 Hldgs %
41.1%
Holding
130
New
17
Increased
26
Reduced
9
Closed
10

Top Buys

Rank Stock Value
1
TMO icon
Thermo Fisher Scientific
TMO
+$228M
2
PEN icon
Penumbra
PEN
+$104M
3
TNYA icon
Tenaya Therapeutics
TNYA
+$52.8M
4
SGHT icon
Sight Sciences
SGHT
+$42.2M
5
MGNX icon
MacroGenics
MGNX
+$34.4M

Top Sells

Rank Stock Value
1
QDEL icon
QuidelOrtho
QDEL
+$113M
2
PTGX icon
Protagonist Therapeutics
PTGX
+$74.8M
3
SPY icon
State Street SPDR S&P 500 ETF Trust
SPY
+$54.3M
4
MDXG icon
MiMedx Group
MDXG
+$27.1M
5
TRIL
Trillium Therapeutics Inc.
TRIL
+$20.3M

Sector Composition

Rank Sector Weight
1 Healthcare 91.48%
2 Financials 0.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCKT icon
1
Rocket Pharmaceuticals
RCKT
$348M
$470M 7.08%
15,802,802
+812,516
+5% +$29.6M
SPY icon
2
State Street SPDR S&P 500 ETF Trust
SPY
$778B
$375M 5.65%
873,255
-123,000
-12% -$54.3M
ALNY icon
3
Alnylam Pharmaceuticals
ALNY
$36.3B
$318M 4.79%
1,683,362
– –
MRTX
4
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$264M 3.98%
1,492,532
+35,000
+2% +$5.63M
TMO icon
5
Thermo Fisher Scientific
TMO
$211B
$238M 3.58%
+416,000
New +$228M
MASI
6
DELISTED
Masimo
MASI
$225M 3.4%
832,540
+6,330
+0.8% +$1.72M
VCEL icon
7
Vericel Corp
VCEL
$2.3B
$220M 3.32%
4,517,570
– –
CLDX icon
8
Celldex Therapeutics
CLDX
$2.77B
$211M 3.18%
3,908,947
– –
NTRA icon
9
Natera
NTRA
$37.5B
$208M 3.13%
1,862,234
+150,000
+9% +$17.2M
PTCT icon
10
PTC Therapeutics
PTCT
$6.37B
$197M 2.97%
5,293,966
– –
ILMN icon
11
Illumina
ILMN
$29.4B
$196M 2.95%
496,309
– –
ESTA icon
12
Establishment Labs
ESTA
$2.72B
$166M 2.5%
2,319,138
– –
DRNA
13
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$153M 2.31%
7,582,396
+60,537
+0.8% +$1.67M
TNDM icon
14
Tandem Diabetes Care
TNDM
$1.17B
$139M 2.09%
1,160,734
+13,326
+1% +$1.47M
GMED icon
15
Globus Medical
GMED
$10.4B
$128M 1.93%
1,670,811
– –
AXNX
16
DELISTED
Axonics, Inc. Common Stock
AXNX
$127M 1.91%
1,943,864
– –
RNAM
17
DELISTED
Avidity Biosciences
RNAM
$118M 1.78%
4,795,000
+800,000
+20% +$17.4M
GH icon
18
Guardant Health
GH
$19.5B
$116M 1.74%
925,342
+7,089
+0.8% +$842K
CCCC icon
19
C4 Therapeutics
CCCC
$376M
$111M 1.68%
2,494,965
+345,737
+16% +$14.8M
ISEE
20
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$109M 1.65%
6,722,624
– –
FULC icon
21
Fulcrum Therapeutics
FULC
$248M
$109M 1.64%
3,855,291
+650,000
+20% +$12.3M
TXG icon
22
10x Genomics
TXG
$5.87B
$107M 1.61%
734,481
– –
PEN icon
23
Penumbra
PEN
$12.5B
$103M 1.55%
+385,194
New +$104M
DMTK
24
DELISTED
DermTech, Inc. Common Stock
DMTK
$100M 1.51%
3,118,665
– –
STOK icon
25
Stoke Therapeutics
STOK
$1.82B
$92.7M 1.4%
3,644,248
– –
1
2 3 4 5

Similar funds

MG
Mather Group Chicago, Illinois $10B AUM 15.14% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $9.98B AUM 4.97% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OAM
OP Asset Management Helsinki $9.95B AUM 30.22% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

RTW Investments's Q3 2021 Portfolio in Review

As of Q3 2021, RTW Investments held 130 positions worth $6.63B, up 0.06% from $6.63B the previous quarter. Its ten largest holdings account for 41% of the portfolio.

RTW Investments deployed $439M of net new capital in Q3 2021, opening 17 new positions and adding to 26 existing holdings. Its largest new stake was Thermo Fisher Scientific: 416,000 shares worth $238M.

By sector, the portfolio is most concentrated in Healthcare at 91% of assets, up from 88% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $74.8M trimmed.

  • RTW Investments's largest Q3 2021 buy was Thermo Fisher Scientific: 416,000 shares worth $238M.
  • RTW Investments added most to MacroGenics in Q3 2021, an estimated $34.4M increase.
  • RTW Investments's biggest Q3 2021 reduction was Protagonist Therapeutics, cutting an estimated $74.8M.
  • RTW Investments fully exited QuidelOrtho in Q3 2021, selling an estimated $113M.
  • RTW Investments's ten largest holdings make up 41% of its $6.63B portfolio in Q3 2021.
  • RTW Investments opened 17 new positions and closed 10 in Q3 2021.
  • RTW Investments's portfolio value rose 0.06% quarter-over-quarter to $6.63B.

Based on RTW Investments's 13F filing for Q3 2021, filed 15 Nov 2021.